Molecular characteristics of premalignant breast lesions


Cite item

Full Text

Abstract

The article is devoted to clinical and prognostic significance of the levels of markers, traditionally defined in breast cancer in the cohort of patients with benign breast diseases. The following parameters are analyzed: steroid hormone receptors, the proliferative activity of the micro-RNA, the expression of COX-2, E-cadherin gene amplification of c-erb-B2 and TP53. Identify the most important of them in various benign diseases and akzhe most typical changes that occur in diffuse dyshormonal dysplasia, fibroadenomas and atypical hyperplasia.

About the authors

I V Vysotskaya

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: vysotskaya.irina@mail.ru
проф., д-р мед. наук ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Russian Federation, Moscow, ul. Trubetskaia d. 8, str. 1

V P Letyagin

N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

проф., д-р мед. наук, гл. научный сотр. ФГБУ «РОНЦ им. Н.Н.Блохина» 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E M Pogodina

N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. научный сотр. ФГБУ «РОНЦ им. Н.Н.Блохина» 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Семиглазов В.Ф. Скрининг рака молочной железы. Практическая онкология. 2005; 11 (2): 60-5.
  2. Колядина И.В., Поддубная И.В., Комов Д.В. Скрининг рака молочной железы: мировой опыт и перспективы (обзор). Рос. онкол. журн. 2015; 1: 42-6.
  3. Sasaki Y, Takagi K, Akashira J-I et al. Immunolocalisation or estrogen - producing and metabolizing enzymes in bening breast disease: comparison with normal breast and breast сarcinoma. JCA 2010. Cancer Sci 2010; 101: 2286-92.
  4. Cheng et al. Differential regulation of estrogen receptor (ER) alpha and ERbeta in primate mammary gland. J Clin Endocrinal Metab 2005; 90: 435-44.
  5. Gruvberger-Saal et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha - negative breast carcinoma. Clin Cancer Res 2007; 13: 1987-94.
  6. Колядина И.В., Поддубная И.В., Франк Г.А. и др. Прогностическое значение рецепторного статуса опухоли при раннем раке молочной железы. Соврем. технологии в медицине. 2012; 4: 48-53.
  7. Stettner et al. The relevance of estrogen receptor-β expression to the antiproliferative effects. Mol Cancer Ther 2007; 6 (10): 2626-33.
  8. Zhao et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci 2014; 71 (8): 1549.
  9. Лукавенко И.М., Андрющенко В.В., Кононенко Н.Г. Клиническое значение экспрессии рецепторов эстрогена, прогестерона и маммаглобина при предопухолевой патологии молочных желез в практике хирурга - маммолога. Журн. клін. та експерим. мед. дослідж. 2013; 1: 51-4.
  10. Yu H. Estrogen - receptor status patients with breast cancer. Breast Cancer Res Treat 1996; 40: 171-8.
  11. Diaz L.К, Sahin A, Sneige N. Progesterone receptors and estrogen receptor alpha expression in normal breast tissue and fi broadenomas. Ann Diagn Pathol 2004; 8: 23-7.
  12. Коган И.Ю. Мастопатия, новые подходы к диагностике и патогенетической терапии. Акушерство и женские болезни. 2010; 1: 66-9.
  13. Колядина И.В., Поддубная И.В., C.J.H. van de Velde и др. Прогностическое значение экспрессии р53 у больных раком молочной железы I стадии. Современная онкология. 2013; 15 (2): 17-21.
  14. Колядина И.В. Автореф. дис. … док - ра мед. наук. М., 2015; с. 164-9.
  15. Schmitt F.C, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995 Jul; 176 (3): 233-41.
  16. Bartek J, Bartkova J, Vojtesek В et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J of Cancer 1990; 46 (5): 839-44.
  17. Younes M, Lebovitz R.M, Bommer K.E et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995; 26 (2): 155-8.
  18. Rohan T.E, Hartwick W, Miller A.B, Kandel R.A. Immunohistochemical Detection of c - erbB - 2 and p53 in Benign Breast Disease and Breast Cancer Risk. J National Cancer Institute 1998 September 2; 90 (17).
  19. Lidereau R, Collin F, Arnal M et al. Benign Breast Disease: Absence of Genetic Alterations at Several Loci Implicated in Breast Cancer Malignancy. Clin Cancer Res 15.
  20. Akhtar K, Bharduaj S, Naim M et al. Diagnostic Value of Cytokeratin 5 and Cytokeratin 6 in Benign and Malignant Lesions of Breast. Annals of Pathology and Laboratory Medicine 2015; 2 (4): 403-10.
  21. Hartmann L.C et al. N Engl J Med 2015; 372: 78-89.
  22. Tjoe J.A, Neitzel G, Singh M et al. Does expression of estrogen receptor, progesterone receptor, and HER2 in atypical breast lesions predict a subsequent clinically significant event? J Clin Oncol 2014; 32 (Suppl 26; abstr 34).
  23. Visscher D.W et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. JNCI 2008; 100 (6): 421-7.
  24. Lingle W, Negron V, Bruzek А, Hartmann L. Centrosome Amplification is Greatest in Benign Breast Lesions Associated with an Increase in Risk of Cancer. Poster presentation: San Antonio Breast Cancer Symposium, Annual Meeting, December 16, 2006. San Antonio, 2006.
  25. Chan J.A, Krichevsky A.M, Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-33.
  26. Zhao J-J, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor - alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-86.
  27. Stinson S, Lackner M.R, Adai A.T et al. TRPS1 targeting by miR-221/222 promotes the epithelial - to - mesenchymal transition in breast cancer. Sci Signal 2011; 4 (177): 41.
  28. Medina P.P, Slack F.J. MicroRNAs and cancer: an overview. Cell Cycle 2008; 7: 2485-92.
  29. Tili E, Michaille J-J, Wernicke D et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 2011 Mar 22; 108 (12): 4908-13. doi: 10.1073/pnas.1101795108
  30. Wu H, Zhu S, Mo Y.Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19 (4): 439-48.
  31. Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010; 11: 926-35.
  32. Козлов В.И. Роль молекулярных маркеров в диагностике и лечении рака молочной железы. Автореф. дис. … канд. мед. наук. Новосибирск, 2014.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).